Better Medicines Through Signaling Dynamics

13

Years in business

2

Therapeutic Areas

42

Publications

Immuneering’s novel drug candidates spare healthy normal cells by modulating signaling dynamics to focus therapeutic impact against tumor cells.

Platform

Immuneering’s innovative R&D platform has a long history of reproducibly identifying drug targets, pinpointing biomarkers, stratifying patients and elucidating drug mechanisms of action. Currently, our platform is employed to drive Immuneering’s internal pipeline and those of our high value R&D relationships with select partners.

Pipeline

Immuneering is advancing a robust pipeline of oncology and neuroscience drug candidates that uniquely disrupt cellular signaling dynamics with the potential for game-changing efficacy and better safety across large, high unmet need patient populations.

Publications

Our commitment to rigor and reproducible data analysis is validated by a long track record of peer-reviewed publications. In collaboration with our partners in pharma and the scientific community, our research has been featured in a number of high-impact journals.

Publications

Join the Team